The reiteration of a Buy rating and the maintenance of a $95 price target by a Benchmark analyst could instill confidence in investors and potentially lead to a positive short term impact on Ligand Pharmaceuticals' stock price. Analyst ratings are influential in shaping market sentiment, and a Buy rating suggests that the analyst sees the stock as undervalued or poised for growth, which can encourage investment.